NewsBenzingaArcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending Benzinga 2026.10.20 12:38 (GMT+0) Open on Benzinga Other news Meta, IBM, Texas Instruments, LAM Research and Tesla: Why These 5 Stocks Are on Investors' Radars Today This wonky maneuver kept Mark Zuckerberg from fleeing a California billionaire tax WD-40 Company (WDFC) Q4 2026 Earnings Call Transcript Las Vegas Sands Corp. (LVS) Q3 2026 Earnings Call Transcript Meta Platforms, Inc. (META) Q3 2026 Earnings Call Transcript Tesla says it will start selling Cybercabs by end of year
Meta, IBM, Texas Instruments, LAM Research and Tesla: Why These 5 Stocks Are on Investors' Radars Today
